For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $28.56 down -1.42% from its previous closing price of $28.97. In other words, the price has decreased by -$1.42 from its previous closing price. On the day, 1.34 million shares were traded. ARQT stock price reached its highest trading level at $29.09 during the session, while it also had its lowest trading level at $28.3.
Ratios:
For a deeper understanding of Arcutis Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 15 ’25 when Burnett Patrick sold 11,500 shares for $28.94 per share. The transaction valued at 332,851 led to the insider holds 98,307 shares of the business.
Patrick Burnett bought 11,500 shares of ARQT for $332,851 on Dec 15 ’25. On Dec 01 ’25, another insider, Matsuda Masaru, who serves as the insider of the company, sold 1,657 shares for $30.23 each. As a result, the insider received 50,091 and left with 150,641 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 3498376960 and an Enterprise Value of 3421082880. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.00 while its Price-to-Book (P/B) ratio in mrq is 21.73. Its current Enterprise Value per Revenue stands at 10.761 whereas that against EBITDA is -103.079.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.71, which has changed by 1.079684 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $31.77, while it has fallen to a 52-week low of $11.13. The 50-Day Moving Average of the stock is 7.02%, while the 200-Day Moving Average is calculated to be 56.26%.
Shares Statistics:
For the past three months, ARQT has traded an average of 2.43M shares per day and 2034970 over the past ten days. A total of 120.29M shares are outstanding, with a floating share count of 107.63M. Insiders hold about 12.14% of the company’s shares, while institutions hold 96.72% stake in the company. Shares short for ARQT as of 1765756800 were 13235954 with a Short Ratio of 5.44, compared to 1763078400 on 13717750. Therefore, it implies a Short% of Shares Outstanding of 13235954 and a Short% of Float of 13.28.
Earnings Estimates
The company has 7.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.03, with high estimates of $0.12 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.15 and -$0.31 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.45, with 7.0 analysts recommending between $0.78 and $0.25.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $109.83M this quarter.It ranges from a high estimate of $112.6M to a low estimate of $107M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $71.36MFor the next quarter, 6 analysts are estimating revenue of $98.23M. There is a high estimate of $102.31M for the next quarter, whereas the lowest estimate is $94.6M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $361.3M, while the lowest revenue estimate was $353.6M, resulting in an average revenue estimate of $357.45M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $467.32M in the next fiscal year. The high estimate is $470.1M and the low estimate is $462M.
